Abstract
Key questions remain over theranostics. How can your company secure key
successes and ideals in personalized medicine - aiming the right drug at the
right person and at the right time. Plus with increased FDA regulation, how
can we guarantee that that specific drug is safe for that individual. These
issues are not going away, but one report can make it a lot easier for you and
your company.
This report delivers to you a clear understanding of the commercial prospects
of theranostics. The fusion of drug therapy and diagnostics, with the purpose
of optimising efficacy and safety, as well as streamlining the process of drug
development offers you and your company clear opportunities. This emerging
field is generating interest from the healthcare industry and regulatory
bodies, with the associated market expanding continually as the importance of
theranostics is recognised.
Theranostic solutions are playing an increasingly important role in
pharmaceutical R&D - increasing safety, speeding up clinical development and
facilitating regulatory acceptance. Furthermore, theranostics is paving the
way towards the long-held goal of personalised medicine, to the benefit of
patients and payers. Theranostics has also received encouraging support from
regulators such as the FDA. Pharmaceutical, diagnostics and biotechnological
companies cannot afford to overlook this rapidly emerging field. So you should
be sure you corner your percentage of the market immediately.
Theranostics 2007-2012 examines the market for theranostic solutions
critically, through comprehensive primary and secondary research. Importantly,
visiongain discusses theranostics in the context of the wider diagnostics
market. In addition to consultation with experts in industry, this research
involved a detailed study of documents, industrial reports and relevant news.
Importantly, visiongain also applied techniques such as financial forecasting
and SWOT analyses. The result is a comprehensive market-based report with
detailed analysis and informed opinion.
In particular, this report concentrates on the following essential aspects of
the theranostics sector:
- Technologies that drive the theranostics sector
- Key industrial players in theranostics - including partnerships in that
field
- Forecasts of the global theranostics market from 2007-2012, including
forecasts of the molecular diagnostics market and principal market segments
within theranostics
- Drivers and opportunities in the theranostics sector
- Restraints and threats in the theranostics sector
- Assessments of relevant business models, technological solutions and
associated issues
- Coverage of future trends in the sector
- Insight from a survey with experts from industry and academia
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for theranostics from
2007-2012
- To discover predicted revenues, growth rates and other key metrics for
theranostic solutions from 2006-2011
- To receive the views of experts in the theranostics sector
- To determine the forces that influence the market for
theranostics:Competitive characteristics of the market, Drivers, Restraints,
Strengths,weaknesses, opportunities and threats
- To find out where theranostics is heading - both technologically and
commercially
Visiongain predicts that all aspects of theranostics will exhibit strong
growth in revenues from 2007-2012, with significant investments being made by
far-sighted companies in the pharmaceutical, diagnostics and biotechnological
sectors. Although still in its early stages of commercial development,
theranostics will increasingly gain acceptance from stakeholders in
healthcare. Successful participating companies will benefit as a result,
gaining early market prominence from high-value products. But which areas of
theranostics will that be? Find out today by ordering your executive copy of
Theranostics 2007.
| 
View Cart
